French Healthcare

Choose France™

French Healthcare

Prix Galien Best Startup Nominees

October 2023

French healthcare players' humanist, grassroots, scientific and collective approach is guided by key values excellence, universalism, efficiency, science-based progress.

"

French Healthcare

Brought to you by

BUSINESSFRANCE

Business France is the national agency supporting the international development of the French economy, responsible for fostering export growth by French businesses, as well as promoting and facilitating international investment in France. It promotes France's companies, business image and nationwide attractiveness as an investment location, and also runs the V.I.E international internship program. With branches in 10 cities, our North American team has both the knowledge and the experience to facilitate trade relations between France, Canada and the US.

THE GALIEN FOUNDATION

The Galien Foundation serves as a vehicle for the open exchange of ideas that drive science and new innovations. Its vision is to catalyze the development of the next generation of innovative treatment and technologies that will improve health and save lives. Its scope is global, and our commitment to progress in medicine is both measurable and concrete. Its members express this through the establishment of productive relationships to build lasting bridges between the commercial research enterprise and local communities engaged in public policy, science, finance, academic research and the media.

In collaboration with

orcom
Expertise Comptable Audit & Consei

Cure
BY DEERFIELD

Northwell Health

Join the movement with 4Moving Biotech, where we fast-track innovation for better health.

With our unique quadruple-action 4P004 and ground-breaking in silico trials, we accelerate drug development, aiming for effective disease management and better quality of life.

Every advancement we make is a vital stride towards restoring movement, promoting health, and revitalizing lives.

4movingbiotech

4movingbiotech.com

4MOVINGBIOTECH

4Moving biotech is a cutting-edge clinical stage company at the forefront of osteoarthritis (OA) research. Inspired by the groundbreaking work of renowned rheumatologist Prof. Francis Berenbaum, the lead product is based on targeting metabolic-induced low-grade inflammation using GLP-1 analogues. These analogues, used for type-2 diabetes mellitus and obesity, offer a promising path towards a Disease-Modifying OsteoArthritis Drug (DMOAD). With potential applications for age-related diseases, this innovation strives to provide a breakthrough solution for OA patients.

Your contact

Revital Rattenbach
CEO
revital@4p-pharma.com
4movingbiotech.com
Lille & Paris, France

11-50 employees | Clinical stage | Share capital | Since 2014

Biotech

As We Know

Develop digital health to accelerate patient care

Our first mission

Reduce diagnostic wandering in rare diseases with

RDK Rare Disease Knowledge®



Built for

Collaboration

Based on

Trusted sources

Remains

Free to use

Co-developed by orphanet and TEKKARE



As We Know

As We Know is a mission-driven company characterized by social objectives whose purpose is to share medical and scientific knowledge by developing digital tools for healthcare professionals and patients to facilitate disease management. Its first mission : Reduce diagnostic wandering in Rare Disease with RDK (SaMD class1). RDK (Rare Disease Knowledge), a unique public-private partnership, is an app distributed by As we Know and developed by Tekkare and Orphanet (Inserm). By enabling earlier detection of diseases and directing patients to expert centers, the app reduces the physical, psychological and societal damage caused by diagnostic wandering.

11-50 employees | Medical support | Financial Partnership

Since 2023 | Digital Health

Your contact

Bruno SARFATI

CEO & Founder

bruno.sarfati@asweknow.com

asweknow.com

Montrouge, France

BIOMUNEX Pharmaceuticals is a clinical-stage biopharmaceutical company based in Paris, led by an international team, focused on the discovery and development of disruptive immuno-therapeutics in oncology, thanks to its proprietary next-generation bi- and multi-specific antibody, the BiXAb® platform

Biomunex is developing a disruptive biological approach, the so-called MAIT-engagers, that redirect MAIT cells to kill cancer cells, which will become a true game changer in the field of cancer immunotherapy

- Together with Antibody-Drug Conjugates, bi- and multi-specific antibodies are considered as the most potent and promising next generation of biotherapies to improve the overall survival in cancer. Therapeutic antibodies have been the most efficient and value-added modalities on the market over the last 2 decades, particularly in oncology. As a result, seven of the top ten pharmaceutical products in terms of sales are therapies based on the use of therapeutic antibodies, including the global leader in sales (superior to € 20Bn), Keytruda (Merck), a monoclonal antibody in immuno-oncology.
- BIOMUNEX has created and developed a next-generation, best-in-class bi- and multi-specific antibody platform, the BiXAb® platform. This platform enables BIOMUNEX to generate bi- and multi-specific antibodies from any pair of monoclonals as building blocks, in a straightforward, fast and cost-effective fashion, that can be used to leverage disruptive biological modalities in immuno-oncology.
- BIOMUNEX has demonstrated that the BiXAb® platform offers all key properties expected of an ideal bispecific antibody technology: modularity, speed, excellent drug-like properties and manufacturability, flexibility & versatility. Our first BiXAb antibody lead has demonstrated excellent industrial production properties and is starting clinical phase 1, with an expected superior anti-cancer activity in several hematological malignancies and solid tumors. BIOMUNEX is now a clinical-stage company.
- BIOMUNEX' BiXAb platform has been validated by two transforming out-licensing deals: first, a platform licensing deal on several programs with Sanofi in 2019: https://www.biomunex.com/wp-content/uploads/2019/01/190115-Biomunex-Sanofi-EN.pdf, that brought a significant upfront, whereas BIOMUNEX is expecting to milestone payments; second, a product-focused license and co-development deal (with upfront, milestone payments, royalties), in parallel to a strategic investment with Onward Therapeutics in 2021: https://www.biomunex.com/wp-content/uploads/2022/01/210216-Biomunex-License-EN.pdf.
- BIOMUNEX' main objective is to invent disruptive biological approaches. BIOMUNEX' pipeline includes a large panel of BiXAb® bispecific antibodies in development and several disruptive biology driven programs for immuno-oncology, in late discovery or development stage.
- The proprietary flagship program, the BiXAb-MAIT engagers, uses the BiXAb platform to redirect MAIT cells to specifically engage and kill cancer cells in solid tumors. MAIT cells are a subset of T cells that were discovered by Dr. O. Lantz, a key opinion leader in immuno-oncology from France's leading cancer center Institut Curie (Paris), who is now a scientific adviser to BIOMUNEX. The BiXAb-MAIT engager approach was invented thanks to a collaboration between BIOMUNEX and Institut Curie, leveraging its recognized expertise in T cell biology. This disruptive and unique approach will overcome the limitations of competitors, CD3+ T-cell engagers, such as cytokine release syndrome (a common and potentially fatal toxicity), yield superior and durable clinical responses in solid tumors, and increase safety, enlarging the therapeutic window.
- BIOMUNEX has a strong IP & patent position. Based on original technology invented by a European academic consortium, BIOMUNEX has developed the unique BiXAb® platform, filed additional patent family applications, and has recently expanded its IP portfolio with other patent families (e.g., MAIT engagers).
- The company has established a world-class team, with labs based in the bioincubator of Cochin hospital in Paris, France, with a US affiliate, in Cambridge, MA, BIOMUNEX Inc. The management team is made up of an experienced group of international C-level executives and drug developers in oncology.
- BIOMUNEX' growth has been supported by a very efficient combination of equity and non-dilutive financing. Our current goal is to fundraise and partner, to notably advance two BiXAb antibodies targeting MAIT to clinical development and continue developing the BiXAb-MAIT engager approach.

Pierre-Emmanuel Gerard, MD, MBA. Founder and CEO Biomunex Pharmaceuticals. pe.gerard@biomunex.com

Biomunex Pharmaceuticals

BIOMUMEX Pharmaceuticals is a biopharmaceutical company, based in Paris and Cambridge, MA, focused on the discovery and development of breakthrough immunotherapies using its unique and proprietary BiXAb® technology to create next generation bi- and multi-specific antibodies for oncology. BIOMUNEX is notably developing a disruptive biological approach, the MAIT-engagers, that redirect MAIT cells to kill cancer cells, which will become a true game changer in the field of cancer immunotherapy. This unique approach will overcome the limitations of competitors, CD3+ T-cell engagers, such as cytokine release syndrome, yield superior clinical and durable responses in solid tumors, and increase safety, enlarging the therapeutic window.

Your contact

Pierre-Emmanuel GERARD
President & Founder
pe.gerard@biomunex.com
biomunex.com
Cambridge, MA & Paris, France

11-50 employees | Clinical stage | Dilutive & non-dilutive | Since 2014

Biotech

BiPER Therapeutics

Value Proposition

Despite growing success of immunotherapies, existing chemotherapies and the development of targeted therapies, 50% of patients suffering from cancer remain without solutions. BiPER Therapeutics aims at bringing solutions to those patients through the modulation of new pathways in the metabolism of cancer. We focus on gastrointestinal cancers and melanoma with priority for indications with orphan status

Product description & Innovation

- *Patented "First in Class" safe small molecules to treat orphan cancers*
- *Cancer Metabolism – Our drug candidates push selectively cancer cells to suicide, by targeting BIP/GRP78 a key protein involved in cancer cell survival and correlated to poor prognosis*
- *Demonstrated Efficacy and Tolerability In Vivo in oral administration in Gastric and Colorectal Cancers*



Market

- *Gastro-intestinal cancers (Gastric and Esophageal, Colorectal, Pancreatic Cancers) and Skin Cancers*
- *Priority to Orphan Cancers with Orphan Drug Designation status like Gastric Cancer (1 Million Cases – 54 Billions $ Global Sales forecast @2029 horizon)*



Survival curve in Gastric cancer patients with low and high BiP/GRP78
Chen et al. Cell Death Dis. 2018 Nov; 9(11): 1070

Competition

- *One compound in early clinical stage but not specific to BiP (multiple MoA) and IV administration that will limit its clinical benefit, market penetration and revenues*
- *Our candidate has demonstrated strong selectivity, in vivo efficacy in monotherapy and in combination with 3 standards of care (Immunotherapies and Chemo) **in oral administration** with an excellent tolerability and very good pharmacological profile*

Key company milestones



Business Model

- *Traditional Biotech start-up model with the objective of financing / developing a portfolio of small molecules until clinical PoC and then monetize them.*
- *Our development will be focused on the sale of our assets to pharmaceutical groups with the capacity to finalize the development and then bring it to market.*
- *As a result, our development and value creation will be focused primarily on preparing the sale of these assets, through Business Development / Licensing / Partnering activities*

SECTOR

TAG *Biotech*

FIELD OF ACTIVITY

TAG *First In Class Small Molecule*

Co-Founders

Mehdi Chelbi *Msc Drug and Corporate Development Expert*
Rachid Benhida *– DR CNRS. Expertise in Chemistry*
Stéphane Rocchi *– DR INSERM. Expertise Molecular Biology*
Cyril Ronco *– MC-HDR. Expertise in Chemistry et Drug Design*

Executive Team

Mehdi Chelbi *– CEO*
Michael Cerezo *– CSO*
Samson Fung – CMO
Nedra Tekaya – Senior Scientist

IP STATUS

3 patents composition of matters
1 patent method of use
1 patent formulation
Global exclusive license signed

STAGE OF PROGRESS

BPR001 Selected Candidate for IND Enabling studies to treat gastro-intestinal cancers In Vivo PoC in Gastric and Colorectal cancer in oral administration in mono and combo with ICIs and Chemotherapy - Regulatory Preclinical Development

BPR002 at hit-to-lead stage to treat Melanoma (triple wild type) - Regulatory Preclinical Development at Q4 2023 horizon

AWARDS/DISTINCTIONS logos

CONTACT

Mehdi Chelbi - CEO
+33 6 63 87 88 61
mehdi.chelbi@biper-tx.com

Biper Therapeutics

BiPER Therapeutics develops first-in-class therapeutics against cancers with high unmet medical needs. The first drug candidate, BPR001 is first-in-class inhibitor of BIP, a key protein involved in survival and resistance of cancer cells. BPR001 opens a new way to treat cancers by pushing cancer cells to burn out. BPR001 is 1 year away starting clinic trials and positioned to treat patients with advanced gastro-intestinal cancers as BPR001 demonstrated proof of concept efficacy in several gastro-intestinal cancer models in monotherapy and in combination with chemotherapeutics and immunotherapies.

Your contact

Mehdi CHELBI
CEO & Co-founder
mehdi.chelbi@biper-tx.com
biper-tx.com
Strasbourg, France

2-10 employees | Preclinical stage | Seed | Since 2021

Biotech

DeepLife: the digital twin of the cell for drug discovery

DeepLife is a pioneering systems biology company that leverages omics data and deep learning to model cells and efficiently engineer their behavior, as well as predict cell reactions to different perturbations. By integrating omics data and interpretable AI, we generate digital twins of cells, virtual replicas of various cell types or cell lines, enabling seamless manipulation, testing, and analysis in a computer environment.

DeepLife is leading the effort to apply this concept of the digital twin of the cell to drug discover. Through the integration of omics data, we can generate a comprehensive picture of unhealthy cells and leverage this understanding to develop effective therapeutic interventions and thus predicting how molecules or a change in the environment is affecting the cell. Using DeepLife digital twin of cells as an “in silico lab”, we can rapidly test billions of drugs and drug combinations and identify the mechanisms of action which are most likely to restore a diseased cell to its healthy state.

This approach derisks our own drug development pipeline by enabling the testing of known drugs and millions of drug combinations, identifying new targets, performing in silico testing, and discovering new drugs or classes of molecules to address these targets, whether they are newly developed or repurposed.



We offer a range of products, including an omics data catalog and comprehensive in silico cell types specific modeling. These solutions tackle crucial aspects of target and biomarker identification, cell engineering, and optimization of cell lines and testing new compounds in silico. **Artificial intelligence by the means of our digital twin of the cell** is data-driven, streamlined, giving us the ability to analyze complex data sets and find patterns that can tell us how genes are linked to diseases, and how diseases are linked to biological processes. DeepLife is able to process tons of existing scientific Omics data and uncover new targets for therapeutics at unprecedented pace, and even predict clinical trial outcomes based on clinical data in ways we never imagined before.

DeepLife.

ww.deeplife.co

• Les informations d’un contact : Nom, email et téléphone, site web
Jonathan Baptista / CEO
jonathan.baptista@deeplife.co
www.deeplife.co



DeepLife

DeepLife is a startup developing a platform combining state-of-the-art deep learning algorithms. Their goal is to supplement in vitro testing with in silico simulations and discover molecular triggers to efficiently engineer cell behavior. The company is working closely with biotech and pharmaceutical companies to accelerate their target identification processes.

Your contact

Johnathan BAPTISTA
CEO & Co-founder
jonathan.baptista@deeplife.co
deeplife.co
Paris, France

2-10 employees | R&D Support | Seed | Since 2019

Digital Health

Gleamer

Reveal the full potential of imaging with AI

At Gleamer, we are dedicated to pioneering the future of imaging by constructing the ultimate AI co-pilot. Our commitment lies in making optimal care an attainable reality for all.

Adopted worldwide

30 Countries

15M Exams/year

800 Institutions

Committed to science

10 Publications

30 Clinical studies

Alexander R. Margulis award
Scientific excellence 2022

contact@gleamer.ai
www.gleamer.ai

Gleamer

Gleamer has developed AI software to help radiologists diagnose and detect bone trauma lesions in scans, among other conditions. Gleamer's core flagship BoneView software, which is known as an "AI companion for bone trauma x-rays,". They also developed ChestView for detecting pulmonary pathologies. Gleamer's products have been CE certified, and FDA cleared. The software boasts some 6,500 users across 650 institutions in 24 countries.

Your contact

Christian ALLOUCHE

CEO & Co-founder

christian.allouche@gleamer.ai

gleamer.ai

Cambridge, MA & Paris, France

51-200 employees | Clinical Stage | Serie B | Since 2017

Digital Health

LATTICE MEDICAL
Soft Tissue Reconstruction

LATTICE MEDICAL
3D PRINTED RESORBABLE IMPLANT FOR BREAST RECONSTRUCTION

LATTICE MEDICAL, a clinical stage company of 25 talented people, develops advanced solutions in reconstructive surgery. Our innovative solutions combine the advantages of current techniques to make the procedure simpler, more accessible to more people and less expensive. LATTICE is the result of a 6 years collaborations between M.D. P. DANZE (Biochemnist), M.D. P. GUERRESCHI (Plastic Surgeon, CMO), M.D. P. MARCHETTI (Biologist, CSO) and PhD J. PAYEN (Engineer, CEO).

The company develops a breakthrough device in the field of breast reconstruction after cancer. Indeed, 1 in 8 women will suffer from breast cancer and in developed countries, 240,000 patients will have a mastectomy each year. Following this procedure, only 20% of these patients will benefit from breast reconstruction.

Today, three reconstruction techniques exist: breast implant, lipofilling and flap surgery. Each of these methods has drawbacks such as long-term foreign body, complex surgical procedure, multiple surgeries and are costly for the health care system which limits the number reconstructions among patients. For these reasons, patients today are looking for a natural, less invasive and durable breast reconstruction.

Lattice Medical is developing a new implantable technology: a resorbable Tissue Engineering Chamber (TEC) called MATTISSE® combining biomaterials, 3D printing and tissue engineering. MATTISSE® allows the regeneration of autologous adipose tissue in 6 months and in the meantime the bioresorbable implant will slowly degrade until it's resorption between 18 to 24 months. Finally, the breast volume is restored in a natural way, without presence of long-term implant. Thanks to our 3D printing platform, we simplify the process and make it more accessible, customizable and less expensive.



Figure 1 - Operating technique for the MATTISSE tissue engineering chamber

Link to video: https://youtu.be/a0pJwj5kEUo

MATTISSE® is in clinical stage for breast reconstruction since July 2022 in France, Spain & Georgia. We have target of 10 patients until end of 2023 for the FIH study and a target of 50 patients by the end of 2024 for the CE Mark under MDR. Clinical trials are planned in 2025 in US under PMA process for FDA clearance.

LATTICE MEDICAL is looking to raise funds by the end of 2024 in order to:

- Start IDE clinical trials in US for FDA clearance
- Commercialization in Europe and licencing agreements in the aesthetic field
- Expand our production capacity
- Develop other products thanks to our technology and platform

Our ambition is to replace silicon implants in all breast surgeries



Figure 2 – MATTISSE mechanism of action

Lattice Medical

Lattice Medical is a biomedical start-up that has developed a patented 3D technology that enables the natural regeneration of adipose tissue, bringing enormous improvements in breast implant procedures. The MATTISSE bioprosthesis is made of 3D-printed biomaterials allowing the regeneration of autologous adipose tissue, is fully bioabsorbable, and is adapted to the individual morphology of the patient. Breasts are thus entirely reconstructed from the patient's own tissue, and no foreign bodies are introduced.

Your contact

Julien PAYEN
CEO & Co-founder
julien.payen@lattice-medical.com
lattice-medical.com
Lille, France

11-50 employees | Clinical stage | Series A | Since 2017

Medtech

NEXT GENERATION VACCINE AND IMMUNO PLATFORM

FOR FASTER, BROADER, AND MORE EFFECTIVE RESPONSE.

Longer lasting and more effective vaccines to address health challenges

LinKinVax

LinKinVax

LinKinVax disrupts vaccine development using a unique dendritic cell-targeting vaccine platform to address numerous diseases and variants, such as cancers or evoloving viruses, faster and to be able to massively scale using existing protein based production worldwide, at very competitive cost, and limitating risks of recurring epidemic outbreaks. DC-targeting is pursued due to the pivotal role dendritic cells play in ensuring an optimal stimulation of the immune system. It enables the development of vaccines that elicit a potent and wider-ranging immune response, while maintaining a high level of safety.

Your contact

André-Jacques AUBERTON-HERVÉ

President & Founder

andre.auberton@linkinvax.com

linkinvax.com

Paris, France

11-50 employees | Clinical stage | Series A | Since 2020

Biotech

AONYS® DELIVERY PLATFORM

The Trojan horse for undruggable assets

Patient centricity is a key driver for Medesis Pharma. Most of drug candidates in cancer and neurodegenerative diseases are highly invasive, associated with important side effects or with limited benefits.

With these challenges in mind, Medesis Pharma applied its technology to identify new treatment options that are convenient, safe and easy to administer.

Medesis Pharma aims to be an R&D platform licensing assets at phase II (proof of concept).

Enthusiasm and daring to try are in the company's DNA.

Buccal administration

Invisible for immune system and protected transport in plasma

Intracellular delivery by lipoprotein receptors

Crossing the blood-brain barrier

www.medesispharma.com



Medesis Pharma

Medesis Pharma is a company developing new drug candidates to treat diseases for which there are no effective treatments, based on breakthrough technology designed to deliver therapeutic molecules. Its mission is also financial, as only appropriate funding will enable to implement development plans and validate the efficacy and safety of each drug.

Your contact

Solene GUILLIOT

Chief Medical Officer

& Head of R&D

solene.guilliot@medesispharma.com

medesispharma.com

Paris, France

11-50 employees | Clinical stage | IPO | Since 2003

Biotech

RESOLVE
HEAL
REGENERATE

RESOLUTION OF INFLAMMATION

Resolution pharmacology targets failed inflammation resolution, the underlying driver of continued tissue destruction in chronic inflammatory pathologies and degenerative conditions.

At MED'INN'PHARMA, our mission is to develop an array of pro-resolving therapeutics that provide durable and safe therapeutic alteratives.

Our platform allows the production of highly biocompatible human set of molecules in a natural balanced composition, working synergistically to actively resolve inflammation, heal and regenerate tissue, while preserving immune function.

RESOLVIX®

A NEW BIOLOGICAL DRUG CANDIDATE TO TACKLE INFLAMMATORY AND DEGENERATIVE DISEASES

►100% of human origin◄
►100% of human composition◄
►A perfect set of pro-resolutive molecules◄
►Reprograms dysregulated immune cells◄
►Favors tissue healing◄

MIP Pharma

a secretome company

LEVERAGING OUR INNOVATIVE TECH PLATFORM TO DELIVER FIRST-IN-CLASS RESOLUTION MEDICINE



MED'INN'Pharma

The immune system has the capacity to defend the body against threats by triggering inflammatory responses that self-resolve during the resolution phase that terminates inflammation and activates tissue healing and regeneration. However, wherever unsuccessful, unachieved resolution nests chronic inflammation causing degenerative diseases. Med'Inn'Pharma's unique platform technology generates drug candidates composed of perfect sets of human molecules released by conditioned human cells. Resolvix, 100% human-origin Med'Inn'Pharma's lead candidate with pro-resolutive properties, activates termination of inflammation, tissue healing and regeneration. With its growing pipeline, Med'Inn'Pharma will revigorate safely the immune system to efficiently tackle inflammatory and degenerative diseases.

2-10 employees | Preclinical stage | Private share | Since 2017

Biotech

Your contact

Sylvain PERRUCHE

CEO

perruchesylvain@hotmail.com

medinnpharma.com

Besançon, France

Burden Lightened

Efficiency Amplified

Safety Elevated

MAESTRO



Moon Surgical

Moon Surgical is a medical device company developing a surgical robot for laparoscopy assistance. It broadens access to minimally invasive techniques for surgeons and optimizes resource utilization in the operating room. The Maestro System from Moon Surgical provides complete control and technology that can adapt to every condition faced, resulting in increased operating room efficiency.

Your contact

Anne OSDOIT

CEO

aosdoit@moonsurgical.com

moonsurgical.com

San Carlos, CA

Paris, France

11-50 employees | Clinical stage | Series B | Since 2019

Medtech

Op2Lysis - Accelerated market access for cerebrovascular diseases

Cerebral hemorrhage is an unmet medical need

CEREBRAL HEMORRHAGE





Hemorrhagic

- × **0 Approved therapy**
- × **High Burden (50% of stroke burden while cerebral hemorrhage represents 20% of all strokes)**

- ✓ Local administration
- ✓ A surrogate marker offered by the MISTIE-III trial*
- ✓ Time window for treatment initiation larger than for ischemic stroke*

Life threatening condition
&
Unmet medical need

* Hanley et al. The Lancet (2019)

Tackling Cerebral Hemorrhage
Unique Selling Proposition and Value of O2L-001



O2L-001 solution	Op2Lysis
HIGH EFFICACY. Improved efficacy (>40% evacuation vs alteplase)	
SAFE. > 80% lower untargeted activity (vs alteplase). Absence of pro-neurotoxicity	
EASY. injection procedure	

NANOp2Lysis®: a game-changing platform to accelerate market access

Vectorization — O2L-001, Nano-formulation for extended-release of OptPA

Manufacturing & Process — Strong know-how in particle manufacturing and purification. Manufacturing from the bench to the industrial scale

Translational modeling — Peer-reviewed model for high translationality from bench to bed. Surogate marker used to anticipate best dosage in patients

Regulatory — Orphan drug designations granted for OptPA both in the USA and in Europe to accelerate clinical development and market access (Conditional / accelerated approval)

Supported by European Innovation Council · Co-funded by the European Union · Wallonie recherche SPW · bpifrance



Op2Lysis

Op2Lysis is developing new treatments for patients suffering from the hemorrhagic form of stroke. The company is developing its own platform, a combination of vectorization technology, industrial know-how enabling clinical-quality production, and preclinical expertise including the establishment of predictive and translational models - a first in this field. O2L-001, the first product resulting from this technology, will shortly enter regulatory toxicology to reach combined Ph1&2 clinical stage end of 2024.

Your contact

Christophe GAUDIN
Co-founder
christophe.gaudin@op2lysis.com
op2lysis.com
Boulogne-Billancourt, France

2-10 employees | Preclinical stage | Seed | Since 2016

Biotech

WE LEVERAGE CUTTING-EDGE TECHNOLOGIES,
COMBINING BIOTECH AND NUCLEAR INDUSTRIES,
TO DEVELOP BREAKTHROUGH TREATMENTS IN **ONCOLOGY.**

Based on its unique expertise in the production of lead-212 and the development of radioligand therapies, Orano Med aims to become the oncology leader in **targeted alpha therapies** to offer innovative solutions for **patients with high unmet medical needs.**

oranomed
^{212}Pb for Targeted Alpha Therapy

Learn more at
oranomed.com

Orano Med

Orano Med develops a new generation of radioligand therapies against cancer using the unique properties of lead-212, a rare alpha-emitting radioisotope. Its pipeline combines lead-212 with diverse biological vectors for an almost unlimited range of applications in oncology. AlphaMedix, its most advanced program in phase II clinical trial, achieved very promising results with a best-in-class efficency potential. Orano Med also develops a robust manufacturing and supply chain for these drugs building a unique industrial platform. Orano Med seeks to bring to the market the first targeted alphatherapies to offer breakthrough solutions for patients with unmet medical needs.

11-50 employees | Clinical stage | Financial Partnership | Since 2009

Biotech

Your contact

Julien DODET
CEO & President
julien.dodet@orano.group
oranomed.com
Paris, France

ReST THERAPEUTICS | RECOVERY FROM STRESS AND TRAUMA

To cure and prevent PTSD



To stop the progression of Alzheimer

By revisiting NMDA-R based Neuroprotection with FENM



ReST Therapeutics

ReST Therapeutics, a Biotech created in 2020, is entering the clinical stage with its first drug candidate FENM. FENM is a proprietary NME selectively targeting two NMDA subtypes. FENM demonstrated long term neuroprotection in AD models, on par with the most recent disease modifying proposals, while surpassing ketamine in stress induced cognitive impairment models and achieving complete fear release, making PTSD and AD the natural therapeutic targets for FENM development.

ReST Therapeutics is looking for partners to accelerate its development in the US.

2-10 employees | Clinical stage | Seed | Since 2020

Biotech

Your contact

Gilles RUBINSTENN

CEO & Founder

gilles.rubinstenn@rest-therapeutics.com

rest-therapeutics.com

Montpellier, France

Rondol



Our Partners

Rondol Technology

Rondol Industrie specializes in micro-extrusion technology tailored for the pharmaceutical sector. We pride ourselves on our expertise in adapting hot extrusion techniques to the micro-scale, ensuring solutions that are both easy to upscale and compliant with industry standards. Our flagship product, the all-in-one vertical twin screw extruder, epitomizes our commitment to innovation. Designed with a unique vertical architecture, it's both cost-effective and minimizes contamination risks. With precise temperature control, we manage active principles and complex polymers efficiently. We currently offer a 10mm screw size and plan to launch a 21mm version soon. This aligns with our legacy of impactful contributions, such as the formulation of tablets that significantly aided in the AIDS epidemic in Africa.

11-50 employees | R&D Support | Since 2012 | Medtech

Your contact

Victoire DE MARGERIE
Chairman & Founder
victoire@rondol.com
rondol.com
Nancy, France

SeqOne GENOMICS

Enabling personalized medicine through better genomics

Personalized medicine can deliver new cures and improve disease prevention while reducing healthcare costs. SeqOne works with healthcare providers and pharmaceutical companies to deliver genomic analyses that enable personalized medicine to make the world a healthier place.

Connect to a source of deeper genomic insights

www.seqone.com

SeqOne Genomics

SeqOne develops genomic analysis solutions that deliver actionable clinical insights to improve patient outcomes in the fields of cancer and inherited diseases. The aim is to make genetic testing easier and more accessible to accelerate the adoption of personalized medicine. SeqOne's latest offering, SeqOne | IntensiveGene. reduces turnaround times and the qualified personnel required to obtain actionable genomic insights, making it easier for patients in ICUs (Intensive Care Units) to enjoy the benefits of genomic medicine.

Your contact

Jean-Marc HOLDER

CSIO

jm.holder@seqone.com

seqone.com

Montpellier, France

51-200 employees | Genomic analysis for clinical applications | Series A | Since 2017 | Digital Health



Driving a step change in the treatment of cancer.

The world leader in CTPS1 inhibition for the targeted treatment of cancer.

Pioneering a novel class of oral drugs that specifically inhibit the enzyme cytidine triphosphate synthase 1 (CTPS1), regarded the 'Achilles heel' for haematological cancers.

A new approach with the potential to yield a highly selective, safe and effective cancer treatment for blood cancers and solid tumours.

Visit **step-ph.com** to find out more.

Step Pharma

Step Pharma has discovered and developed inhibitors of CTPS1 (cytidine triphosphate synthase 1) for the treatment of cancer and autoimmune diseases. Step Pharma's lead program STP938 is a potent, selective, oral inhibitor of CTPS1 with demonstrated potent anti-tumor activity in models of leukemia and lymphoma. STP938 entered clinical development in 2022 for the treatment of relapsed and refractory T-cell and B-cell lymphoma. Future plans include biomarker selected solid tumour studies with ovarian cancer in 2024.

Your contact

Andy PARKER

CEO

ap@step-ph.com

step-ph.com

Saint-Genis-Pouilly, France

2-10 employees | Clinical stage | Series B | Since 2014

Biotech

OdySight

Discover OdySight, the first mobile vision tracking game



Prescribed by doctors, played by patients !

OdySight is a prescription-only mobile application to be used regularly between your ophthalmology consultations.

The application offers visual tests adapted from those performed in the clinic. Your test results are transmitted to your doctor in real time.

YOU PLAY, WE CARE

Tilak Healthcare

Tilak Healthcare is a unique videogame studio where like-minded and passionate people create fun mobile medical games for patients with chronic diseases. There is a huge burden on the healthcare system; doctors and caregivers need new, validated tools and resources to improve access. At Tilak Healthcare, every product on the market is clinically validated, developed with physician and patient advocates, compliant with medical device regulations, and protects the patient's privacy.

Your contact

Edouard GASSER
CEO & Co-founder
egasser@tilakhealthcare.com
tilakhealthcare.com
Paris, France

11-50 employees | Clinical stage | Series A | Since 2016

Digital Health

Usense

Smart devices and AI for personalized and predictive health for all

Improving diagnosis time and accessibility is the next paradigm of healthcare as it is the only way to improve people's health and prevent diseases

Analyzing easily and precisely biological fluids is the most relevant way to make early diagnosis accessible for all and everywhere

Jimini is the first integrated solution for urinalysis that provides quantitative biological results in a few seconds

Usense www.usense.healthcare contact@usense.healthcare

Usense

Usense aims to facilitate early diagnosis for all by generalizing the use of medical devices and artificial intelligence. It is a necessary cornerstone for significantly improving the healthcare system. The first product, Jimini, tackles urinalysis. Current methods provide limited information or require complex and time-consuming processes. Jimini offers instant and accurate measurements of various biomarkers. It combines ultra-miniaturized optical and electroanalytical sensing technologies to create a unique health fingerprint, then processed by AI to produce quantitative biological results. Jimini is a new companion to improve diagnostic speed and accuracy, and allow mobility into healthcare facilities, paving the way for tomorrow's care.

11-50 employees | Clinical stage | Financial Partnership

Since 2019 | Medtech

Your contact

Guillaume LEMETAIS
CEO & Co-founder
glemetais@usense.healthcare
usense.healthcare
Boulogne-Billancourt, France

Volta Medical is a data-inspired, AI solutions electrophysiology company whose mission is to aid in the assessment of **complex atrial fibrillation.**

TRANSFORMING
ELECTROPHYSIOLOGY DATA
INTO **AI SOLUTIONS**

Volta Medical

Volta Medical creates cutting-edge software solutions using machine and deep learning algorithms to assist operators during cardiac ablation procedures. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space.

Your contact

Théophile MOHR DURDEZ
CEO
t.mohr-durdez@volta-medical.com
volta-medical.com
Marseille, France

51-200 employees | Clinical stage | Series B | Since 2016

Medtech

WHITELAB
GENOMICS

UNLEASH THE POTENTIAL OF GENOMIC MEDICINE USING AI

LEVERAGE THE POWER OF OUR PROPRIETARY PLATFORM TO ACCELERATE & TRANSFORM DRUG DISCOVERY & DEVELOPMENT

Our next-gen platform

W-KNOW
Genomic Medicine Knowledge powered by AI

W-LOAD
Promoter Selection and Expression Cassette Design

W-MAP
Target Discovery and Cellular Biomarkers ID

W-VECTORIZE
Viral and Non-Viral, Capsid Engineering, Bioproduction optimization

More than 40 projects successfully completed in collaboration with academic institutions, biotech and pharmaceutical companies across the US and Europe

Inserm La science pour la santé From science to health
UCSF
Flagship Pioneering
GENETHON INNOVER POUR GUERIR
Nantes Université
ICM Paris Brain Institute Search, find, cure, for you, with you

Our capabilities

Target Discovery
- Expression profiling
- Cellular biomarker atlas
- Epigenetic signatures
- Protein structure
- Interaction simulations
- Biomedical knowledge

Vector Design
- Viral capsid & envelope
- Non-viral vectors
- Transduction optimization
- Biodistribution prediction
- Immunoreactivity modulation

Payload Design
- Promoter/enhancer choice
- Transgene expression modulation

Bioproduction
- Capsid viability
- Helper function optimization
- Full/empty ratio



WhiteLab Genomics

WhiteLab Genomics develops a proprietary platform that leverages graph knowledge technology and machine learning to help companies discover and design new genomic therapies to face challenges such as optimizing payload, vector design, assessing genotoxicity, and identifying optimal experimental protocols for in vivo and in vitro strategies. Whitelab Genomics guides its clients through the in-silico development phases to provide patients with access to new genomic therapies.

Your contact

David DEL BOURGO
CEO & Co-founder
ddelbourgo@whitelabgx.com
whitelabgx.com
Paris, France

11-50 employees | R&D Support | Series A | Since 2019

Biotech

BIOTECH

affini T™

The solution provided by Affini-T is highly innovative and incor¬porates several differentiated scientific approaches to improve T cell fitness, persistence, and durability. These innovations have broad implications for future research and significant potential for those patients with high unmet medical needs. Firstly, Affini-T utilizes the expression of naturally occurring potent and selective TCRs, which allows for the identification of highly active and tolerable therapies. Coordinating the CD4/ CD8 T cell response is another key aspect, as it enables a deep and durable anti-tumor effector function. By integrating the CD8α/β co-receptor, the peptide/MHC recognition by the TCR is amplified, thereby enhancing the T cell response. Coordinated CD4/ CD8 T cell responses are facilitated by Affi¬ni-T's approach, leading to increased functional persistence of its therapies. This coordinated response involves the expres¬sion of selected TCRs and CD8α/β co-receptor chains, ena¬bling CD4+ T cells to target and respond to the tumor.

ascidian

Treating the underlying cause of disease by replacing entire mutant exons via rewriting RNA is now in reach. Ascidian scientists have achieved the goal of developing RNA exon editing therapeutics with evidence-based potential to redefine the treatment of human disease by addressing the underlying cause of disease. As we move our lead program toward the clinic, we are also progressing a diversified pipeline of programs using our pro¬prietary platform for rewriting RNA by exon editing in other retinal diseases, as well as in neurological, neuromuscular, and other genetically defined diseases. Ascidian is currently focused on using its platform to replace mutant exons with wild-type exons, enabling cells to tune their own precise protein expression in order to treat disease in patients with few or no treatment options. But the potential of the Ascidian approach goes much further.

BigHat BIOSCIENCES

Licensing cutting-edge technology from a research lab is the traditional starting point for biotech startups. BigHat, unlike the majority of biotechs, invented its platform technologies after establishing the company. BigHat's organic research and development has led to advancements in various fields of science and technology, from affordable cell-free protein synthesis to novel active learning algorithms. As pioneers in successfully integrating these technologies into the Milliner platform, BigHat has become a leader in applying AI/ML to drug discovery. Milliner allows BigHat to develop a unique pipeline of therapeutics for patients suffering from today's worst diseases in addition to significantly reducing the development cost and timeline associated with discovering new therapeutics. This approach will not only reduce the cost-burden on some of the most intractable and costly diseases but also improve patient outcomes by introducing more effec¬tive drugs than what is available today.

Cellarity
A Flagship Pioneering Company

• Significantly expanded diagnostic capability, enabled in at-home monitoring setup
• Compared to other technological solutions requiring addi¬tional hardware (wearable devices,medical technology) Car¬dioSignal has the capability to scale aggressively in all layers of the society because smartphones are already distributed widely in society
• Demonstrated ease-of-use in target population of 60+ years of age with significant CVD risk factors, with onboarding pos-sible within 15 minutes from access activation to first measu¬rement
• Is easy to distribute through health systems and remote care providers for both early detection / screening purposes in remote locations as well as utilize it existing remote patient monitoring setups
• Is a powerful tool for clinical trials (existing medication / disease progression studies and as a clinical trial identification tool)

delix

Until recently, innovation in the development of novel neuro¬psychiatric medicines has been minimal and with one in five adults in the US currently suffer from a psychiatric disorder, according to The National Alliance on Mental Illness, there is a clear and unmet need for better solutions. On the near horizon, psychedelic-assisted therapies have shown great promise. However, these treatment paradigms require in-cli¬nic administration and medical observation due to the halluci¬natory effects, the invasive routes of administration, and risk for cardiac events. Not only does this lead to high treatment costs but also requires time, travel, and other life disruptions¬making access challenging. Even if access was not a hurdle, the contraindications such as neuropsychiatric or cardiac co¬morbidities make the addressable patient population to these transformative therapies estimated at <5% of the patients in need. Delix's mission is to bring the healing power of neuro-plasticity-promoting psychoplastogens to the other 95% of patients who could benefit.

emendobio

CRISPR-based genome editing was revolutionary upon its discovery; however, its approach using the wild-type form of the nuclease has its limitations, specifically regarding safety and precision. Recent years have brought forth a resurgence of innovation in gene editing, helping to refine existing CRISPR technology. At EmendoBio, we are engineering precision into genetic medicine via our novel OMNI™ Technology Platform. The process increases genome accessibility to cover 86% of the genome, enabling scientists to broaden gene targeting. With more of the genome available, we're now able to treat a broader list of disease indications with highly effective editing and no off-target effects. Amajor concern with CRISPR in its wild-type formis the rela¬tively high rate of off-target effects, which have been viewed with a frequency of >50%.

FLARE THERAPEUTICS

There is a high unmet need for new therapies for patients with urothelial carcinoma (UC), which accounts for 90% of blad-der cancers and 10 to 15% of kidney cancers. In 2022, 81,000 people in the USA are expected to be diagnosed with bladder cancer. UC, also described as bladder cancer, is the 10th most common cancer type worldwide, with the most important risk factor being tobacco smoking, which accounts for ~50% of cases. Approximately 25% are diagnosed with muscle-invasive disease. Five-year survival for patients with locally advanced¬muscle-invasive disease is < 40% in the USA and falls to 8% with distant metastasis. Platinum-doublet chemotherapy, PD(L)1 checkpoint inhibition, and antibody-drug conjugate therapy (enfortumab-vedotin and sacituzumab-govitecan) are the standard of care for most patients with advanced disease, but the median overall survival of front-line patients treated with the latest regimens is only 2 years.

gameto

Fertilomimics the ovarian environment outside of the body, providing a young ovarian support cell signaling environment that allows for egg maturation outside of the body. Unlike cur¬rent treatments that require 10 to 14 days of hormone injec¬tions to increase the number of mature eggs in the body prior to retrieval, Fertilomatures and increases the quality of eggs outside of the body, resulting in a solution that is more natu¬ral, requires fewer hormone injections, lowers risk of com¬plications, has higher success rates and reduces overall cost. By making these processes less painful and expensive, Fer¬tilo could lower barriers to adoption of IVF and egg freezing, improving options and access for l couples who want to build families and allowing women to take control of their timelines.
Beyond Fertilo, Gameto's technology can be used to generate a broad range of reproductive treatment solutions addressing areas including menopause and diseases of the reproductive systemand ovarian drug discovery.

BIOTECH

Generate: Biomedicines

Generate: Biomedicines is the first drug generation company pioneering a machine learning-powered generative biology platform with the ability to create new drugs on demand across a wide range of biologic modalities. The Generate Platform – which is a continuous loop to generate, build, measure, and learn – can drastically increase the speed at which targets and therapeutics are identified and validated. This will improve the specificity of target engagement by generated proteins and reduce the time and cost of identifying and developing clinical candidates.

geneos THERAPEUTICS

Immunotherapies have dramatically impacted the treatment of cancer in recent years, but a significant unmet need exists for therapies that can robustly generate CD8+ T cell responses and for those which can safely be combined with checkpoint inhibitors. Checkpoint inhibitors appear only to be effec¬tive when CD8+ T cells are present in the tumor microenvi¬ronment, and our PTCVs have been shown to reprogram the tumor microenvironment driving impactful CD8+/CD4+ T cell responses against the tumor. Further, with our industry-lea¬ding, unique ability to include virtually all of a patient's tumor neoantigens in the creation of his/her PTCV, this creates a highly targeted immune response which we are observing in extensive mechanism of action studies from ongoing analyses of our clinical data. Additionally, in the event of tumor immune escape, we can simply redesign and remanufacture an upda¬ted PTCV to resume vaccine effectiveness.

Immunis

Our immune system is the most critical determinant of our health, affecting our susceptibility to disease and ultimately, quality of life as we age. Immune dysregulation is at the root of numerous agerelated diseases. Since 2019, there has been a steady increase in scientific publications on the secretome ameliorating diseases. Secretomes are an emerging class of biologics, rich in active biomolecules secreted by a cell. They play significant roles in cell communication, development, and immune responses, meaning they can potentially address complex, age-related diseases. However, secretome thera¬pies are still a newly emerging area of research.
The secretome has recently been studied as an alternative therapeutic approach to administering stemcells directly, which have a controversial history as a biomedical treatment.

JUNO diagnostics

Built on a foundation of cutting-edge technology and driven by an unwavering commitment to improving the human condi-tion, Hazel™ is a pivotal turning point in prenatal screening. Its advancements pave the way for transformative applica¬tions beyond the realm of prenatal health, offering new ave¬nues for early detection and proactive interventions, including within the fields of organ health and oncology. By harnessing the power of advanced technology, the Hazel clinical platform promises to reshape the healthcare landscape, unlocking a future where timely interventions can improve health out-comes. As the world's first capillary-based cfDNA screening test, Hazel™ introduces a paradigm shift in prenatal care, redefining accuracy, accessibility, and convenience.

JURATA THIN FILM

Jurata's innovative solution addresses major short comings of current pharmaceutical supply chain by establishing a simple and rapid production process that increases manufacturing efficiency, removes dependance on costly, specialized cold chain infrastructure, and enables needle-free delivery.
Our patented technology immobilizes vaccines and other bio¬logical therapeutics into a solid thin film matrix, preserving the three-dimensional structure and thereby retaining biologi¬cal efficacy. The resultant films are completely thermostable, enabling storage of these life-saving therapeutics at ambient temperature, and removing the need for cold chain logistics. At the point of administration, films can either be delivered via the oral mucosa (sublingual/buccal), or rehydrated for deli-very via intranasal spray, as well as intramuscular, subcuta¬neous, or intravenous injection.

ProfoundBio

Rina-S is a highly promising development candidate for ova¬rian cancer and multiple additional tumor types that are underserved. Its potent anti-tumor effect along with a well-tolerated and manageable toxicity profile also points to the potential of a cornerstone therapy in diverse combination set¬tings and treatment lines. ProfoundBio is developing multiple novel ADCs thatmay address the unmet need in broad solid tumor indications, and the superior hydrophilic linker techno-logy has enabled first-in-class or best-in-class potential for many promising tumor targets. Besides Rina-S, several other ProfoundBio ADC programs are either in first in human clinical study (PRO116014,15, a CD70-directed ADC [NCT05721222]) or in IND-enabling preclinical development.

promontory THERAPEUTICS

PT-112 is a robust immunogenic cell death (ICD)-inducing anticancer agent at the leading edge of small molecule immu¬notherapy.With demonstrated clinical activity and tolerability, its novel mechanism of action represents a cornerstone to solving unmet needs in immuno-oncology. Distinct frombio¬logics, PT-112 provides a viable solution for challenges with T-cell-directed approaches, including intracellular targeting. PT-112 is well tolerated, with safety data to date lacking im¬munerelated adverse events typically associated with immune checkpoint inhibitors. Together, these properties make this an appealing approach for cancer patients.
Central to PT-112'smechanism is inhibition of ribosomal bio¬genesis (RiBi) in cancer cells, inducing downstream organelle stress culminating in ICD and anticancer immunity. Due to cancer cells' heightened reliance on RiBi for aberrant proli-feration, they are extremely sensitive to PT-112-induced RiBi inhibition, meaning cell death is selective to cancer cells.

TESSERA

Tessera's goal is to make any genomic alteration needed (fro¬ma single nucleotide change to a wholegene insertion), in the specific cells where it is needed, to address diseases of high unmet need. Tessera's hope is that in the future, a child born with a severe genetic disease may receive a single adminis¬tration of a potentially curative GeneWriter and grow up wit-hout ever learning the name of the disease they were born with; that cancer patients can receive a single IV Infusion that engineers their T cells in vivo - within their own body - to tar¬get and eradicate their tumor cells; and that patients who are predisposed to serious common diseases have the option to rewrite their genome to remove the mutations that predispose them to these conditions.

MEDTECH

ACORAI

Acorai has developed the first handheld, non-invasive intra¬cardiac pressure monitor to improve work-flow efficiencies and patient out-comes. The unique and superior technolo¬gy is built on the patented SAVE Sensor System, combining Seismocardiography(SCG), Acoustic (PCG), Visual (PPG), and Electrocar-diography (ECG) sensors, as well as with one of the largest datasets of its kind. This creates accurate, absolute and actionable measurements within minutes, providing direct estimates of Right atrial pressure (RAP), pulmo-nary pressure (PAP), pulmonary cap-illary wedge pressure (PCWP), which are clinically preferred output for heart failure treatment. The solution improces time and cost efficiency, in-cluding removing delays in treatment and enable proactive care. Acorai allows healthcare professionals to diagnose, risk stratify, treat, and discharge plan with fewer resources, reducing readmissions and hospital costs resulting in average direct hos-pital care savings of $1M p.a.

allergenis

Over 32 million Americans have food allergies, including 1 in every 13 children or approximately 2 in every classroom. As many as 60% are over-diagnosed with current blood and skin testing, causing a mental, emotional, and financial toll on indi-viduals, caregivers, and their families. The gold stan¬dard in diagnosing food allergies is an oral food chal-lenge (OFC) which is anxiety-induc-ing, time and resource intensive, may incur a risk of anaphylactic reactions, and is not widely available in clinical practice. The OFC is also often re-quired by therapeutic products during clinical trials which can inhibit trial enrollment and slow time-to-market for treatment solu¬tions. Allerge-nis' revolutionizing technology was developed by a world leader in Food Allergy diagnosis and management, Hugh A. Sampson, M.D. and validat-ed by innovation focused institutions including Mount Sinai, and Stanford University, amongst others.

brainwatch TECH

BrainWatch is building the first autonomous pupillary moni¬toring system for patients with brain injury. As of today, there is no automatic alternative for frequent, accurate and conti¬nual monitoring of PLR in real time. The device is a first-of-its-kind, NEVER before have the pupils been seen when the eyes are closed! The product allows the medical staff to detect changes in a patient's neu-rological status in real time, taking neuro-assesment to the 21st century. By using BrainWatch, PLR examina-tions can be carried out automatical-ly, allowing for remote and continual monitoring without direct medical contact.
The system is constructed as a head unit and a bedside mo¬nitor, it uses advanced technology of computer vision and AI to continually monitor brain injured patients' pupillary light reflex without opening their eyes.

CARCINOTECH

Reinventing Cancer Research

Innovation is at the very core of what we do at Carcinotech. Carcinotech's technology holds the potential to revolutionise cancer research, of-fering surgeons and oncologists the oppor¬tunity to test treatment options, drug responses and create treatment plans for each patient. Contributing to the rapidly develop-ing sector of personalised medi-cine we hope that in the future our models will allow every individual the opportu¬nity to receive personal can-cer care improving treatments and increasing the chance of survival. Carcinotech sets out to address major challenges facing the cancer industry including replicating tumour microenviron-ments and immune systems of the patients. Carcino-tech's immuno-oncology focused printed tumours developed from the patient's immune cells is our solution to this challenge. Traditional organ-oid models can take up to 90 days to be as¬say-ready, are less reproduc-ible, and are incompatible with high-throughput systems.

CardioSignal

• Significantly expanded diagnostic capability, enabled in at-home moni-toring setup
• Compared to other technologi-cal solutions requiring addi¬tional hardware (wearable devices,medical technology) Car¬dioSignal has the capability to scale aggressively in all layers of the society because smart-phones are already distributed widely in society
• Demonstrated ease-of-use in target population of 60+ years of age with significant CVD risk factors, with onboarding pos-sible within 15 min-utes from access activation to first measu¬rement
• Is easy to distribute through health systems and remote care providers for both early detection / screening purposes in remote locations as well as utilize it existing remote patient monitoring setups
• Is a powerful tool for clinical tri-als (existing medication / disease progression studies and as a clinical trial identification tool)

eyecontrol

INSPIRING COMMUNICATION

EyeControl implements disruptive AI technologies connec¬ting people and bridging information barriers, facilitating bettermedical care and decision-making. Our eye-tracking wearable and innovative platform empower comprehensive, round-the-clock, bi-directional connectivity between patients with communica-tion difficulties (primarily ventilated), their families, and medical teams. The company's value-based care approach of personalized commu-nication is intended tomi-tigate the cognitive decline, diminish health-care costs, and shorten the length of hospital stay. The EyeControl platform is set in place while the patient is sedated and supports the patient from the sedation stages to awareness while enabling the family members and staff to have a better way to interact with the patient 24/7.

healthrhythms

Monitoring and ongoing evaluation of mental disorder (pri¬mary diagnosis) clinical status. Monitoring and ongo-ing eva-luation of mental disorder (as a co-morbid diagnosis) clinical status. Personalized digital interven-tion for mental disorders and sleep disorders.

intelligent THREADS

Once the textile is introduced to a human or animal, the TRT interaction occurs within seconds of enter-ing the body's ener¬gy field. Our technology aids the body in imme-diately releasing and relaxing tight muscles allowing for improved body struc¬ture realignment. In our testing since 2016, on over 10,000+ people, the average initial interaction was a 70% improvement of the body's skeletal structure which in turn lead to a de¬crease inmuscular discom-fort that was due to previous body structural issues.
It is important to realize that when the body structure is out of align-ment the muscles are not being utilized properly. Once the body structure is improved it takes time for the muscles to relearn their proper functions. The body's muscles can take roughly three to six months to completely heal and utilize their new anatomically correct state.

MANTIS HEALTH

The Mantis 3D Digital Loupes is the first ergonomic, stylish, high-reso-lution glasses product for surgery. In the same way that the iPhone en-abled the smart phone industry with its elegant design, the Mantis Loupes ismaking 3D visualization exciting for surgeons with its modern look and "immersive" visual experience. Mantis' adoption in the market has led to the accumulation of a sig-nificant library of 3D video content. This is where the Mantis software team is focusing most of its machine learning efforts - for applications in training, education, and surgical navi-gation. Other future product offerings will be in the areas of miniature 3D cameras, robotics, video sharing and editing through the cloud, and remote augmented reality annotations.

manus NEURODYNAMICA

The NMP innovative concept enables healthcare professionals (HCPs) to test for impairment of the brain's extrapyramidal system that controls accurate movements in a non-invasive way by highly accurately analyzing movement recordings. This is possible with highly accurate sensors together with clini¬cal tasks and ground breaking biomarker extraction tools that quantify subtle movement symptoms - that cannot be seen/ interpreted with the naked eye – and added complex AI for deci-sion support.
This is a unique concept. Whilst

MEDTECH

DIGITAL HEALTH

widely available wearables measure activity and grossmotor skill (course measurements) when the patient is away from the clinic, NMP measures very subtle symptoms that cannot easily be seen or interpreted with the naked eye by the HCP. NMP helps the HCP see and interpret these complex symptoms, expressed as biomarkers, and then provides decision support, using AI.

MFTS

Salt Stone provides a natural therapy that has been used by doctors and wellness practitioners for hundreds of years. Most people do not have access to a dry salt therapy treatment center – especially since Covid caused so many to close - so we made it our mission to capture this healing experience and bring it to the home through our innovative, patent-pending halogenerator, in order to empower daily respiratory wellness through ease-of-use, convenience and beautiful design. This is a product that belongs on a counter, not under it. We used proprietary design to create an organic, natural product look and feel so it can live visibly and functionally in a home envi-ronment. We recognize the need for a proven, natural, easy-to-use, affordable at-home respiratory care device in the face of in-creasing respiratory diseases and conditions that prohibit people from breathing freely and living fully.

NeoPrediX

The NeoPrediX B.1 bilirubin prediction algorithm represents a significant advancement in how precisionmedicine is being delivered in neonatal care by enabling clinicians to forecast the dynamic progression of bilirubin levels for up to 60 hours following the last bilirubin measurement. This critical capabi¬lity empowers healthcare professionals to identify newborns who, at the time of discharge, are likely to require photothe¬rapy within the next 60 hours to treat neonatal jaundice. By avoiding unnecessary readmissions, this predictive tool not only mitigates the negative impact on parental bonding and lactation but also elimi-nates the risk of missing cases that could lead to long-term conditions like permanent hearing loss and kernicterus—a condition considered a «never event," making hospitals and clinicians liable. The software can also help to identify which patients are appropriate for photothe¬rapy at home, reducing the daily cost of care from $2000 to $200 a day.

o8t™ OMNISCIENT NEUROTECHNOLOGY

As stated before, by not having patient specific information about why they experience symptoms like suicidal thoughts, hallucinations, cognitive decline etc., we often select the wrong drugs formental illnesses, fail to have viable treatment strategies for functional neurologic diseases and other mys¬terious poorly defined diseases, design clinical trials in ways which have cohort heterogeneity which we are unaware of which dooms drugs to trial failures, and provide inaccurate prognostic and diagnostic information to patients.
Quicktome uses two widely available MRI protocols, advanced machine learning methods, and novel organization and sim-plification of themassive body of neuroscientific knowledge to make understanding the brain simple, cost effective and reproducible. In other words, we made extremely complex neuroimaging into simple, point and click tools which speed up clinical workflows, but provide extremely powerful analytic and treatment options.

Raydiant Oximetry

Traditionally pulse oximeters have been calibrated empirically with healthy volunteers briefly subjected to oxygen deprivation with simultaneous arterial blood gas measurements. This ap¬proach works because the relative size and shape of a human fingertip is similar between subjects. For the transabdominal fetal oximetry application, the size and shape of pregnant abdomens is not similar between sub¬jects, and it is not ethically feasible to deprive unborn fetuses in-utero of oxygen and simultaneously obtain arterial blood gas measurements from the baby.
To overcome these development challenges, we had to in¬novate new methodologies to calibrate pulse oximeters. We created a database of 7,014 virtual pregnant abdomens through computational modeling of photon propagation.

alviss.ai

It allows the deployment of preventive strategies in heart surgery. It would reduce the clinical burden of complications like stroke and allow better allocation of healthcare financial resources.

BLOQCUBE
SMART.SECURE.SPEEDY

The solution is innovative as it includes three key elements - Ipad/ MobileWeb solution, Cloud and a Private Permissioned Blockchain. The Blockchain delivers an algorithimic struc¬ture of trust along with cryptographically anchored security and ensures auditable immutable data. Additionally by using a «Smart Contract» or «ChainCode» we have built a unique finance module that ensures SOX controls, the clinical trials agreement's performance metrics are enshrined in the algo¬rithim so that we can automate a manual process of payments approval, decreases transaction costs for payments using a ecommerce payment rail (STRIPE) then an accounting record is output to the Accounting ERP software and the data brought back to do a budget versus actuals calculation. We used it in rural India pre Covid and demonstrated we can leap frog technology barriers and ensure diversity of trial sub-jects are ensured.

Click Therapeutics

Prescription digital therapeutics have evolved into an enti¬rely new pillar of medicine, poised to dramatically expand and enhance the healthcare industry. As a visionary innovator inventing with and for patients, Click Therapeutics is working to create a world where high-quality prescription digital the¬rapeutics are routinely used to treat disease, offsetting costs and enabling efficiencies in our healthcare system, while ex¬tending access to effective, personalized treatment to anyone with a smartphone, anywhere in the world. Prescription digital therapeutics represent a newmodality of medicine, with software as a treatment for disease. At Click, we have extensively mapped out the brain and identified op¬portunities to target specific circuits tomodulate and induce biobehavioral changes through this new treatment. This me¬chanistic approach, coupled with skill-based learning from-foundational behavioral science creates a synergistic effect, increasing the probability of clinical success and engagement.

DARWIN HEALTH™
PRECISION THERAPEUTICS for CANCER MEDICINE

DarwinHealth has developed the only CLIA-compliant tech¬nologies/tests for: (a) identifying molecular mechanisms controlling the transcriptional identity of normal and tumor cells; and, (b) inferring the ability of small molecule-based therapy to abrogate tumor viability with >90% accuracy. These innovations have been deployed in multiple partnerships with global biopharmaceutical companies to assess the capacity of their assets to directly target tumor checkpoints in priori¬tized cancer subtypes. Moreover, this work has appeared in high impact-factor publications focusing on prioritization of drugs for highly aggressive and/or rare tumors ranging from metastatic gastro-enteropancreatic neuroendocrine tumors, gastrointestinal sarcoma, Wilms and rhabdoid tumors, and aggressive drug-resistant leukemias, tometastatic pancreas, breast, colon, and prostate adenocarcinoma, to neuroblasto¬ma, meningioma, and GBM.

GLX ANALYTIX

At GLX Analytix, we integrate a novel, proprietary biomarker class with AI to advance personalized healthcare. The current absence of biomarkers for chronic diseases leaves patients and caregivers in the dark concerning diagnosis, treatment, and monitoring. We've uncovered that the glycocalyx, an unde¬restimated and largely overlooked structure on blood vessel walls, undergoes specific cleavage patterns by immune cells before invading organs, causing harm. These patterns can be extracted and synthesized from a blood sample, akin to an ac¬tive disease fingerprint. By building a tool to monitor diseases and predict attacks we aim to diminish side effects, enhance

DIGITAL HEALTH

clinical outcomes, improve quality of life, and play a pivotal role in testing and approving new drugs.

GrayMatters Health
Reimagine Mental Health

Prismfor PTSD is the first FDA-cleared non-invasive, self-neu¬romodulation, prescribed, adjunct digital therapy for PTSD. Prismbrings together multiple, different disciplines including psychiatry, advanced statistics and machine learning, the arts and m usic, big data, and UI/UX, creating a comprehensive, accessible, scalable, and efficacious therapy targeting speci¬fic brain processes, with little to no side effects. While other treatment methods offer behavioral or biological approaches, Prismfor PTSD offers both methods simultaneously by trai¬ning patients to lower their own amygdala-derived-EFP-bio-marker. Additionally, as an adjunct therapy, patients can¬maintain existing treatment regimens and clinicians can use Prismto augment treatment responses.

h2o° therapeutics

First and foremost, Parky is a direct-to-patient tool that aims to empower individuals living with Parkinson's disease to take control of their condition.With the complexity of managing their symptoms and adhering to a rigorous medication sche¬dule, Parky provides a user-friendly platform for self-monito¬ring, understanding disease progression, and actively partici¬pating in their own care. Gone are the days of relying solely on pen and paper diaries; Parky offers a comprehensive solution for tracking and managing this fluctuating condition.
Secondly, Parky offers a truly passive experience for patients. Once enrolled, all they need to do is wear their AppleWatch. Parky seamlessly and continuouslymonitors their symptoms 24/7, generating reports in the cloud and providing real-time data for both patients and healthcare professionals. This effortless and non-intrusive approach allows individuals to focus on their daily lives while still obtaining valuable insights into their Parkinson's symptoms.

HelloBetter

HelloBetter's offer is uniquely innovative in three main ways. Firstly, there is no other provider that offers such a compre¬hensive portfolio of courses addressing the most common¬mental health conditions. Secondly, our solution is not just a patient portal, but also a solution for managing providers that provide written, a synchronous (and thus highly scalable) sup¬port to patients via our platform. Thirdly, we utilize an innova¬tive AI engine to combine human guidance with personalized digital content, adapting to individual patient needs. These innovations result in a highly flexible, easily accessible solu¬tion that combines high-tech and human touch in a blend that is uniquely suited to address the vast treatment gap inmental health care. The FDA recently confirmed our innovative status by granting us "Breakthrough Device Designation" for our Panic course – an accolade only bestowed upon products that go above and beyond the current standard of care.

LifeMine

Never before in the history of science, let alone the pharma¬ceutical industry, has genomic search been used to discovery new, highly evolved bioactive small molecules from living or¬ganisms. Prior to LifeMine Therapeutics, so-called «natural products» were discovered by a laborious process involving sifting through thousands of compounds -- chemical search. Genomic search enables the discovery enterprise to exploit the central dogma of molecular biology, which of course under-pins the discovery of biologics, but which had not been applied to genetically encoded small molecules. LifeMine Therapeu-tics expects to advance an entire pipeline of novel medicines discovered by genomic search, deployed inmultiple therapeu-tics areas from cancer to organ transplantation tometabolic disease, fungal infection and beyond.

MEDRhythms

MedRhythms builds products that will usher in the future of neurologic rehabilitation by scaling a music-powered mecha¬nism of action and leveraging advances in sensing technology with software to introduce evidence-based digital therapeutics that address areas of substantial unmet need, while also brin¬ging the potential to address historical gaps in access to care by reimagining the longitudinal care paradigmand enabling patients to engage in their treatment in a home setting.
MedRhythms' platform is based on cutting-edge neuroscience that demonstrates howmusic can profoundly impact the hu-man brain, target specific neural circuitry to enhance clinical outcomes, and boost neuroplasticity. The platform delivers novel, individualized, interventions based on Rhythmic Audito¬ry Stimulation (RAS), that leverages the mechanism of action of auditory-motor entrainment.

MindMics

MindMics, the pioneering force behind in-ear infrasonic he¬modynography (IH), is leading a revolutionary movement by capturing unique Human Audiom Data that has the potential to transform healthcare delivery through smartphones and their accessories, such as earbuds and hearing aids. It's worth noting that earbuds alone hold three times the market share of smartwatches, with an estimated 750 million truly wireless earbuds set to be shipped worldwide in 2024!
Why sound triumphs over light:
Most wearables available today utilize photoplethysmography (PPG) light technology for measuring heart rate and other key biometrics. However, PPG readings, whether from wrist or finger sensors, only scratch the surface of the skin. Factors like skin tone, thickness, perspiration, and bodymass signifi¬cantly impact the accuracy of PPG-based wearables, rende¬ring theminadequate for many individuals.

nova DISCOVERY

Jinkō® is the first clinical trial simulation platform that allows clinical development teams to optimize trial designs with vir-tual patients before running clinical trials on human subjects. With the Jinkō platform and library of disease models, clinical teams can test protocols on an unlimited number of virtual pa¬tients in a matter of minutes to maximize trial success before patient recruitment. Jinko's modular design is purpose-built for ease-of-use and broad accessibility across disease modeling and clinical deve-lopment teams. The streamlined, simple simulation interface enables all team members to collaborate instantaneously. No modeling experience necessary.

PENTAVERE

Preventable events and errors are a leading cause of death and harm to patients every year.
- 25% of all deaths each year are preventable and due to condi¬tions that are treatable with changes in lifestyle, behaviours or access to proper healthcare.
- 33% of avoidable deaths are from cancers
- 23% of avoidable deaths are from heart disease
These avoidable incidents occur because patients are being¬missed in the healthcare system and are falling through the cracks. The ability to identify patients that are eligible for avai¬lable medical treatments and interventions can revolutionize care and outcomes for patients, and save lives.
Pentavere has built a best in class trusted AI system that solves this specific problem, which can have as great an im¬pact on the human condition as the discovery of the next break through medical cure.

Improving healthcare for all

French Healthcare is an innovative public-private initiative aimed at bringing together under a single banner all the players in the French healthcare ecosystem (businesswses, researchers, healthcare professionals, key public stakeholders, etc.) to jointly promote their activities, expertise, technologies and innovations internationally. It helps to trigger a collective approach dynamic that stimulates international cooperation in the field of health and to promote the vision that health, a vector of social progress, must be improved for everyone everywhere in the world.

Jérôme REVOLE
Managing Director,
Healthcare & Life Sciences for
North America

Roxane VALFORT
Healthcare Trade Advisor

Marie-Astrid SEVILLA
Business Unit Manager
Healthcare

Jonathan MOREIL
Healthcare Trade Advisor

Léna ZAÏM
Communication Consultant
Healthcare & Life Sciences
for North America

Pierre ARTUR
Healthcare Intern
North America

Natalia PURKEY
Communication Intern
North America

FrHealthCare_EN

French Healthcare x Business France

French Healthcare